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Echinacea is used for its immunostimulating properties and may have a role in modulating adverse
immune effects of chemotherapy (i.e., use of 5-ﬂuorouracil (5-FU); ﬂuorouracil and its immunosup-
pressive effect). Patients may seek herbal remedies such as Echinacea (Echinacea angustifolia and Echi-
nacea purpurea) for immune stimulation. Echinacea extracts have been prescribed to supplement cancer
chemotherapy for their immune-supportive effects; however, the extracts may also inﬂuence tumour-
genesis. Our study aimed to determine the proliferative effect of the ethanolic blend of E. angustifolia and
E. purpurea on various cancer cervical and bile duct cell lines, including HELA and QBC-939. Various
cancer cells (HeLa and QBC-939) and human vein epithelial cells (HUVEC) were treated with the Echi-
nacea blend sample that was evaporated and reconstituted in Dimethyl sulfoxide (DMSO). As the extract
concentration of Echinacea was increased from 12.5 mg/mL to 25 mg/mL, there was an increase in cell
inhibition up to 100%, which then reduced to 90% over the next three concentrations, 50 mg/mL, 100 mg/
mL, and 200 mg/mL, in HeLa cells; further inhibitory effects were observed in QBC-939 cells, from 9%
inhibition at a concentration of 25 mg/mL up to 37.96% inhibition at 100 mg/mL concentration. Moreover,
this is the ﬁrst study to report the growth-promoting effects of this Echinacea blend in HUVEC, up to 800%
at a dose concentration of 200 mg/mL. Previous studies have suggested that chicoric acid of Echinacea spp.
is responsible for the increased cell growth. The results of this study show that the hydroethanolic extract
of Echinacea herbal medicine promotes the growth of HeLa cells and QBC-939 cancer cell proliferation,
and may interfere with cancer treatment (i.e., chemotherapy drugs such as 5-ﬂuorouracil and Cisplatin
(DDP)). However, the Echinacea blend shows potential in neurodegenerative diseases with growth-
promoting effects in HUVEC. Further animal trials (in vivo effect) measuring dose toxicology are neces-
sary to demonstrate the interaction of this blend with body and tumor growth, and also any positive
synergistic or adverse interaction with chemotherapeutic drugs listed, so as to conﬁrm the current
observation and epithelial tissue growth or regeneration in a neurodegenerative disease model.
Copyright © 2015, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Animal and clinical studies have shown Echinacea spp., in
particular Echinacea purpurea and Echinacea angustifolia, to have
pronounced immunomodulating effects during illness (i.e.,Trobe University, 3086 Vic-
ello).
for Food and Biomolecules,
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).common cold); increase circulating populations of totalwhite blood
cells, monocytes, neutrophils, and NK cells1; enhance macrophage
activation2; and decrease formation of neoplasms.3 Moreover, im-
mune modulation such as T-cell cytokine response (interleukin-2
and interferon-g) has been demonstrated using an acidic water-
soluble extract from E. purpurea (L.) Moench.4 Moreover, Echi-
nacea has been shown to extend the lifespan ofmice, aswell as to be
an effective cancer treatment.5 This potential anticancer effect has
been documented in AKR/Jmicewith thymic lymphoma consuming
an oral preparation of E. purpurea, displaying signiﬁcant suppres-
sion of lymphoma growth possibly via the suppression of cytokinesrsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
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immune response.6 Further, in clinical trials of hepatocarcinoma
with the use of cyclophosphamide (chemotherapeutic agent; gua-
nine alkylating agent), Echinacea supplementation increased the
number of NK cells and their activity.7 In these cancer types and
chemotherapy uses, Echinacea appears to act therapeutically.
During cancer chemotherapy, some chemotherapeutic medica-
tions [5-ﬂuorouracil (5-FU)/levamisole (LMS)] may reduce immune
response; thus, search for an immune-supportive medication is
required (i.e., levamisole).8 Some patients demand a “natural cure,”
as Echinacea has been used in wound healing to treat
glucocorticoid-mediated immune suppression during injury,9 and a
polysaccharide fraction isolated from E. purpurea (EPS-EPOVIIa) has
been shown to reduce chemotherapy-induced leukopenia. 10 Thus,
it could be assumed that it also has beneﬁts in cancer chemo-
therapy, which causes immune suppression (i.e., toxic to hemato-
poiesis), partial anticancer effect, and other cancer indications.
Currently, Echinacea in a multiherbal blend has been used to
effectively treat gastrointestinal mucositis, a common complication
of chemotherapy, reducing the disruption of chemotherapy cycles11
and demonstrating an anti-inﬂammatory action as well. Further, in
human neuroglioma cells, a CO2 root extract of E. angustifolia DC., in
particular the alkamides, showed a COX-2 mRNA stimulatory effect
but did not stimulate prostaglandin synthesis, and thus may inhibit
COX-2-dependent PGE2 formation where there is inﬂammation,12
such as at the site of tumor burden or systemic inﬂammation dur-
ing cancer or elevated cytokine proﬁle, a hallmark of cancer.
In cancer, increased cytokine proﬁles are present, especially
with the use of doxorubicin (with cyclophosphamide or cyclo-
phosphamide) plus 5-FU, whichmay cause cognitive inhibition13 or
epithelial damage. The cytokine modulation by Echinacea extracts
may be related to a reduction in tissue inﬂammation and can be of
beneﬁt in neurodegenerative diseases. Epithelial retinal pigment
cells have been transplanted into patients with neurodegenerative
disorders, e.g., Parkinson disease, and have shown to have a ther-
apeutic effect.14 Thus, the proliferation of epithelial cells during
neurodegenerative diseases, such as Parkinson or Alzheimer's dis-
ease, may have a possible role in their treatment. Moreover,
epithelial tissue surrounds the entire cardiovascular system, and its
regeneration after cardiac failure, or arteriosclerosis, would also be
of beneﬁt, as would be the regeneration of epithelial cells during
cervical or lung carcinoma (i.e., bronchial epithelium).
Interestingly, the action and mechanism of Echinacea and its
phytochemicals vary between not only different diseases, but also
different types of carcinomas. By contrast, evidence also exists that
Echinacea, i.e., chicoric acid component, interferes with cancer cell
growth and has been shown to proliferate and not inhibit HeLa cell
growth.15 Moreover, some phytochemicals in Echinacea pallida
[(8Z,11Z)-pentadeca-8,11-dien-2-one] have been shown to exert a
cytotoxic effect on human T-cell leukemia cancer lines (Jurkat and
HL-60)16; cytotoxic effects were also exerted by polyacetylenes and
polyenes in human pancreatic MIA PaCa-2 and colonic COLO320
cancer cell lines,17 when conjoined with the assumed immunosti-
mulatory effect of Echinacea spp., indicating that it is an ideal
candidate for adjunct therapy during cancer.
A possible concern of using herbal medicines in cancer therapy
(chemotherapy) is that a number of herbs and even foods are able to
upregulate or inhibit P-glycoprotein (cytochrome P450). P-glycopro-
tein is responsible for exporting xenotoxins including pharmaceutical
medicines, i.e., chemotherapeutic products, from the cell. Echinacea is
a documented inhibitor of cytochrome P450 (CYP) 3A4 inhibitor
in vitro and interacts with anticancer drugs such as etoposide (a P450
CYP3A4substrate), causing thrombocytopenic epidose (i.e., hemolytic
anemia).18 Further, a multiherbal mixture (Sambucus Force) contain-
ingE. purpureaandSambucusnigra causedaweakCYP3A4 inhibition19and CYP3A4 inhibition by E. purpurea, showing a weak inhibition
potential towardsCYP3A4-mediated in vitrometabolism.20 Further, in
human interstitial tissues (Caco-2 cells), E. purpurea has been shown
tohaveadose-dependenteffectondigoxinﬂuxfromP-glycoprotein.21
In particular, pentadeca-(8 Z,13 Z)-dien-11-yn-2-one, a phytochem-
ical, extracted from E. pallidawas shown to reduce PgP activity.22 By
contrast, a study on the effect of E. purpurea on inducing CYP3A4
showed that the pharmacokinetics of the CYP3A4 substrate docetaxel
remained unchanged in cancer patients administered 135 mg of
docetaxel (60-minute intravenous infusion) and taking 1 mL of
E. purpurea extract three times daily (t.i.d.; 60 drops total), resulting in
a nonsigniﬁcant change in either the mean area under the plasma
concentrationetime curve for docetaxel or the elimination half-life.23
Lastly, the efﬁcacy of Echinacea spp. are in some instances contradic-
tory, i.e., immunostimulating effects, as the product is susceptible to
adulteration and also sale of unstandardized extracts of Echinacea.
More research is needed to analyze the efﬁcacy of standardized and
quality of commercial supplies of Echinacea hydroethanolic extracts.
The aim of this study was to observe whether the use of a
hydroethanolic root extract of Echinacea blend of E. purpurea and
E. angustifolia, which is indicated for its various actions (i.e., immune
modulation), would interact with cancer cells grown in both HeLa
andQBC-939 cell lines and/or promote the growth of epithelial tissue
[i.e., human vein epithelial cells (HUVEC)] and show potential for
in vivo epithelial proliferation. Furthermore, the study aimed to gain
preliminary evidence to proceed with an animal study to conﬁrm
either proliferation of tumor growth or that the observed effect is a
misrepresentation due to the use of a cell line (i.e., postabsorptive
modiﬁcationof phytochemicals in the Echinaceablend)would render
them an immune stimulatory effect rather than tumor proliferative
effect. Also, the activity of the Echinacea blend was tested using a
noncancerous human epithelial vein cell line “HUVEC” to identify if it
has a role in the treatment of neurodegenerative diseases.
2. Materials and methods
2.1. Cell lines, chemicals, and biochemicals
HeLa (cervical cancer cell), QBC-939 (cholangiocarcinoma),
Beas-2b (lung/bronchial epithelial), and HUVEC cell lines were
kindly donated by Qiao Yao from the Yunnan Tumour Hospital,
Yunnan, China. Echinacea blend hydroethanolic extract (Mediherb
brand) was purchased from Integria Health Care (Warwick, QLD,
Australia). Purity was assessed by the Integria research group led by
Professor Kerry Bone via high-performance liquid chromatography
(HPLC). The 5-FU injection was made by Tianjin Jing Yao Animo
Acid Co., Ltd (Tianjin, P.R. China). Each bottle contains 250 mg 5-FU
in 10 mL of DMSO. Cisplatin (DDP) is manufactured by Qilu Phar-
maceutical (Hainan) Co., Ltd (Hainan, P.R. China), and diluted
250 mg in 10 mL. Both are 99.9% in purity. DMSO, MTT, Dulbecco's
Modiﬁed Eagle Medium: Nutrient Mixture F -12 (DMEM/F12), 10%
Fetal bovine serum (FBS), and 100 u/mL Penicillin/Streptomycin
Solution (P/S) were purchased from Sigma-Aldrich. The assayswere
performed according to the manufacturer's instructions.
2.2. Plant material, extraction, and mass spectrometryeHPLC
One commercial Echinacea blend preparation was purchased
from Integria Health Care (Mediherb brand). The sample compo-
sition was as follows: 40% E. angustifolia (1:2 root extract)/60%
E. purpurea (fresh plant extract) contained in a ﬁnal concentration
of 50% ethanolic extract. The batch number was B155842, with the
expiry in March 2015.
The blend had been analyzed previously for its phytochemical
composition by Matthias et al,24 but the sample was reanalyzed.
S.A. Cichello et al. / Journal of Traditional and Complementary Medicine 6 (2016) 193e197 195Phytochemical analysis was conducted by the Southern Plant Labo-
ratory, Southern Cross University, NSW, Australia. Brieﬂy, the mass
spectrometryeHPLC was conducted as follows: the sample was
injected through a Phenomenex Luna C18 column
(100 mm  4.6 mm ID; 3 mm particle size). The mobile phase used
consisted of water with 0.005% triﬂouroacetic acid (TFA) and aceto-
nitrile (ACN) with 0.05% TFA. The total running timewas 29minutes,
with a gradient elution from 10% water (0.05% TFA):90% ACN (0.05%
TFA) to 5% water (0.05% TFA):95% ACN (0.05% TFA) over the ﬁrst 19
minutes and the remaining time for column re-equilibration.
The standardized extract contained the following identiﬁed phy-
tochemicals: caftaric acid, echinacoside, chicoric acid, and alkyla-
mides. The hydroethanolic extract (100 mL) was evaporated at room
temperature until only solid sediment remained (refer to Fig. 1).
2.3. Determination of proliferative or inhibitory effects of a
commercial Echinacea blend extract on HeLa cells, QBC-939 cells,
Beas-2b cells, and HUVEC
The Echinacea extract was applied to HeLa cells, QBC-939 cells,
Beas-2b cells, or HUVEC to determine either an inhibitory or a
proliferative activity. The Echinacea blend extract was dissolved in
DMSO at a concentration of 12.5 mg/mL, 25 mg/mL, 50 mg/mL,Fig. 1. Test sam100 mg/mL, or 200 mg/mL. A 10-mL volume of growth media was
added to the herbal extract, and the cell suspensionwas centrifuged
at 3000 g for 10 minutes. The supernatant was poured off and
resuspended in 10 mL of media. Cells were counted on a hemacy-
tometer and diluted accordingly, based on the number of cells
needed for the assay. Cells were seeded at 30,000 cells per well.
Twenty-four hours later, following cell seeding in 96-well plates,
the medium was removed from the well and 0.2 mL of a new
medium was added (DMEM/F12, 10% FBS, 100 u/mL P/S). The plate
was incubated for a further 72 hours, and then the medium was
removed from the well, and 0.2 mL of another new medium con-
taining 10%MTT (5 mg/mL) was added (cell staining). The platewas
incubated for another 4 hours, and then the MTT was removed and
0.2 mL DMSO was added. The plate was shaken in the dark for 10
minutes, and then the optical density was recorded using a reader
at 490 nm. Controls for the assay included DMSO, cells alone, and
DPP alone. The cell growth was plotted against Echinacea concen-
tration and compared with the cell growth in doxorubicin alone.
2.4. Statistical analysis
Once the data were collected and processed, the data sets
were tested with 1-way analysis of variance (ANOVA) using SPSSple proﬁle.
Fig. 2. Results of Table 2, displayed as proliferation or inhibitory effect of Echinacea
blend on various cell growth. Y-axis ¼ proliferation rate (%) (þvalue). Inhibition dis-
played as (value) as a percent of DMSO control. X-axis ¼ cell line type.
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mean ± standard error of themean, using n¼ 5, and then converted
into either percent proliferation or inhibition of the DMSO control.
Student t test was used for statistical analyses.
3. Results
Treatment of HeLa cells with Echinacea showed a concentration-
dependent trend from 12.5 mg/mL to 50 mg/mL, followed by pla-
teaus (see Table 1), whereas at 12.5 mg/mL and 25 mg/mL, there was
a slight growth suppression in QBC-939 cells, but a steady sup-
pression at 50 mg/mL, 100 mg/mL, and 200mg/mL (Fig. 2).
This observationwas also noted in case of human epithelial vein
cell line “HUVEC”, but with an eight-fold magnitude increase, as
was seen in the HeLa cells (Fig. 2), whereas no real growth inhibi-
tion or proliferative effect was seen in Beas-2b cells (Table 1).
4. Discussion
In this study, a commercially available Echinacea blend extract
conferred growth-proliferative effects in HeLa cells, QBE-939 cells,
and HUVEC in vitro. Previously, the proliferative activity of Echi-
nacea extracts has been investigated in a number of studies using
cancer cell lines, but not epithelial cells. These cancer cells included
human colon cancer cells (Caco-2 and HCT-116), with the
E. purpurea ﬂower extract displaying a cytotoxic effect, due to the
major phytochemical chicoric acid (main constituent in Fig. 1) that
reduces telomerase activity; induction of apoptosis via DNA frag-
mentation, activation of caspase-9, cleavage of PARP, and down-
regulation of b-catenin25; and thus mitochondrial signaling of
apoptosis. The growth-promoting effect in HeLa cells by Echinacea
root extract has been attributed to cynarine and chicoric acid
in vitro, as evidenced previously by Huntimer et al,15 conﬁrming the
mechanism of effect observed in this current study.
Further elaboration on the phytochemicals present in
E. angustifolia and E. purpurea blend reveals a high relative con-
centration of chicoric acid in this commercial blend. Another
phytochemical is caftaric acid, which belongs to a class of chemicals
known as cinnamates (hydroxycinnamic acids). It has been isolated
from Vitis coignetiae Pulliat, which has been shown to display
antimutagenic effect toward dimethylbenzo[a]anthracene-induced
mutagenesis in mice and inhibit the induction of inﬂammation by
12-O-tetradecanoylphorbol-13-acetate in mice.26 Moreover, in
another study, echinacoside (dose: 1 mg/mL, 10 mg/mL, or 100 mg/
mL) was shown to be protective against tumor necrosis factor-a-
induced apoptosis in human neuroblastoma (SHSY5Y) cells, which
was associated with a correlation of increasing concentration of the
antiapoptotic protein “Bcl2.”27 By contrast, in MCF-7 cells, chicoric
acid showed a proliferative effect in both HeLa and MCF-7 cells,15
rather than an apoptotic effect, reconﬁrming in this study the
proliferation effect observed in HeLa cells.
From these results, it may be proposed that if cancer patients
are also using herbal medicines (i.e., Echinacea spp.) withTable 1
Peak identiﬁcation.
Peak no. RT (min) Fragment ions (M þ H) Compound ID
(tentative or possible) (MW)
1 4.2 d Caftaric acid
2 5.4 d Echinacoside
3 7.3 d Chicoric acid
4 13.5e16.5 248, 246, 232, 286 Alkylamides (major peak,
m/z 248 echinacein)
ID ¼ identiﬁcation; RT ¼ retention time.chemotherapy or anticancer drugs, the phytochemicals in the
Echinacea spp., in this instance E. angustifolia and E. purpurea, may
reduce the effectiveness of the anticancer drug and possibly the
proliferative effects of Echinacea on the cancer cells, as observed in
this study and the study of Huntimer et al.15 This is the ﬁrst
publication to show a growth-promoting effect of an Echinacea
blend hydroethanolic extract in QBC-939 cells, but more impor-
tantly in HUVEC, which can be studied further for treatment of
neurodegenerative disease states. These ﬁndings suggest a role of
Echinacea blend hydroethanolic extract in the regeneration of
epithelial tissue, in particular the venous tissue. Organ damage
during or after congestive heart failure, or due to carcinoma, may
be remedied via the use of a hydroethanolic extract of an Echinacea
blend. However, this publication reports only preliminary in vitro
observation, and more in-depth research in animal models and
also in humans is required to measure the levels of chicoric acid or
its metabolites in plasma and to determine whether there is a
cancer cell proliferative effect in vivo both in animals and in
humans.
5. Conclusion
This study has shown that an in vitro exposure of both HELA and
QBC-939 cells to an Echinacea blend of E. angustifolia and
E. purpurea, as a commercial extract, enhances the growth of both
HELA and QBE-939 cells. The Echinacea blend also promotes the
growth of HUVEC and may have a therapeutic role in neurode-
generative diseases. The effect of an Echinacea extract requires in-
depth study in vivo in animal models to observe tumor growth/
suppression and also its interference with anticancer drugs leading
to proliferation of tumor cells. Conversely, the observation may be
an artifact of in vitro exposure and may not take into account ab-
sorption or posthepatic modiﬁcation of phytochemicals present in
Echinacea and thus the physiological in vivo effects. A more prom-
ising observation is the stimulation of epithelial cells by the Echi-
nacea extract, and encourages further research to examine the
possible vein epithelial cell regeneration and regenerative effects of
the presented Echinacea extract.
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